The infectious disease in vitro diagnostics market size has grown strongly in recent years. It will grow from $15.1 billion in 2025 to $16.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to global infectious disease burden, hospital laboratory expansion, demand for early diagnosis, advances in immunoassays, government disease control programs.
The infectious disease in vitro diagnostics market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to pandemic preparedness initiatives, growth in molecular diagnostics, rising antimicrobial resistance, expansion of diagnostic labs, increased healthcare screening. Major trends in the forecast period include rapid molecular diagnostic adoption, point of care infectious testing, high sensitivity pathogen detection, multiplex diagnostic panels, increased surveillance testing.
The rise in global infectious diseases drove the growth of the infectious disease in vitro diagnostics market during the historic period. Infectious diseases encompass bacterial, viral, fungal, or parasitic infections affecting populations worldwide at a given time, reflecting the overall disease burden. Changes in climate have expanded the habitats of vectors such as mosquitoes, increasing the global prevalence of infectious diseases. Infectious disease in vitro diagnostics support this trend by offering precise and timely diagnostic tools that allow healthcare providers to detect pathogens, initiate appropriate treatment, and control outbreaks efficiently. For example, in October 2024, the World Health Organization reported that approximately 10.8 million people worldwide contracted tuberculosis, with 55 percent men, 33 percent women, 12 percent children and adolescents, and 6.1 percent of cases among individuals living with HIV. Therefore, the rising global prevalence of infectious diseases contributed to the growth of the infectious disease in vitro diagnostics market during the historic period.
Major companies in the infectious disease in vitro diagnostics market are developing innovative products such as rapid detection of multiple gastrointestinal pathogens to enable timely diagnosis, improve patient outcomes, and expand point-of-care testing. Rapid detection of multiple gastrointestinal pathogens involves diagnostic tests that quickly identify several disease-causing microorganisms in the gastrointestinal tract from a single sample. In June 2024, MP Biomedicals, a US-based provider of products, chemicals, and diagnostics, launched immunochromatographic rapid diagnostic kits for gastrointestinal infectious diseases. These kits allow fast and accurate detection of Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. They support rapid, point-of-care qualitative detection, versatile sample use including stool, blood, plasma, serum, water, and food, and are suitable for both clinical and research settings. Using immunochromatographic technology, they support early diagnosis, treatment monitoring, and confirmation of pathogen eradication, offering a combination of speed, precision, and broad pathogen coverage.
In January 2025, Fremman Capital, a UK-based private equity firm focused on healthcare and life sciences investments, acquired a majority stake in DIESSE Diagnostica Senese for an undisclosed sum. Fremman Capital intends to accelerate DIESSE’s international growth and reinforce its position in the specialty in vitro diagnostics market by supporting innovation, expanding the product range for autoimmune and infectious disease diagnostics, and increasing production capacity at DIESSE’s biotech campus, driving long-term sustainable growth. DIESSE Diagnostica Senese is an Italy-based developer of innovative in vitro diagnostics and reagents for autoimmunity, infectious diseases, and hematological testing, serving clinical laboratories worldwide.
Major companies operating in the infectious disease in vitro diagnostics market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare AG, bioMérieux SA, QIAGEN N.V., Becton Dickinson and Company, Hologic Inc., DiaSorin S.p.A., Meridian Bioscience, Quidel Corporation, Revvity Inc., OraSure Technologies Inc., Transasia Bio-Medicals Ltd., Randox Laboratories, Luminex Corporation, Wako Pure Chemical Industries Ltd., Bio-Rad Laboratories Inc., Trivitron Healthcare.
North America was the largest region in the infectious disease in vitro diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease in vitro diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the infectious disease IVD market by raising costs for reagents, diagnostic instruments, and laboratory consumables imported from Asia-Pacific and Europe. Molecular diagnostics and reagent segments are most affected, particularly in North America. While tariffs have created pricing challenges for laboratories, they are also driving regional manufacturing investments and strengthening domestic diagnostic supply chains.
The infectious disease in vitro diagnostics market research report is one of a series of new reports that provides infectious disease in vitro diagnostics market statistics, including infectious disease in vitro diagnostics industry global market size, regional shares, competitors with a infectious disease in vitro diagnostics market share, detailed infectious disease in vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease in vitro diagnostics industry. This infectious disease in vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Infectious disease in vitro diagnostics are laboratory tests performed on samples such as blood, urine, or swabs to detect, identify, and monitor infectious pathogens including bacteria, viruses, fungi, and parasites. These diagnostics enable accurate and timely diagnosis, guide treatment decisions, and support disease surveillance and infection control.
The main product types in infectious disease in vitro diagnostics are instruments, reagents, and software and services. Instruments are tools or devices used to measure and monitor environmental conditions including air, water, soil, and noise. They utilize technologies such as molecular diagnostics, immunoassay, microbiology, hematology, urinalysis, and others. Applications include methicillin-resistant Staphylococcus aureus, Clostridium difficile, respiratory viruses, tuberculosis and drug-resistant tuberculosis, gonorrhea, human papillomavirus, human immunodeficiency virus, hepatitis C, hepatitis B, and more. End-users include hospitals, clinics, diagnostic laboratories, academic research institutes, and other organizations.
The infectious disease in vitro diagnostics market consists of revenues earned by entities by providing services such as serology testing, rapid diagnostic testing, disease surveillance and monitoring, sample collection and processing, and consulting and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease in vitro diagnostics market also includes sales of rapid test kits, culture media, controls and calibrators, molecular sequencing kits, flow cytometry reagents, and point-of-care diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The infectious disease in vitro diagnostics market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to pandemic preparedness initiatives, growth in molecular diagnostics, rising antimicrobial resistance, expansion of diagnostic labs, increased healthcare screening. Major trends in the forecast period include rapid molecular diagnostic adoption, point of care infectious testing, high sensitivity pathogen detection, multiplex diagnostic panels, increased surveillance testing.
The rise in global infectious diseases drove the growth of the infectious disease in vitro diagnostics market during the historic period. Infectious diseases encompass bacterial, viral, fungal, or parasitic infections affecting populations worldwide at a given time, reflecting the overall disease burden. Changes in climate have expanded the habitats of vectors such as mosquitoes, increasing the global prevalence of infectious diseases. Infectious disease in vitro diagnostics support this trend by offering precise and timely diagnostic tools that allow healthcare providers to detect pathogens, initiate appropriate treatment, and control outbreaks efficiently. For example, in October 2024, the World Health Organization reported that approximately 10.8 million people worldwide contracted tuberculosis, with 55 percent men, 33 percent women, 12 percent children and adolescents, and 6.1 percent of cases among individuals living with HIV. Therefore, the rising global prevalence of infectious diseases contributed to the growth of the infectious disease in vitro diagnostics market during the historic period.
Major companies in the infectious disease in vitro diagnostics market are developing innovative products such as rapid detection of multiple gastrointestinal pathogens to enable timely diagnosis, improve patient outcomes, and expand point-of-care testing. Rapid detection of multiple gastrointestinal pathogens involves diagnostic tests that quickly identify several disease-causing microorganisms in the gastrointestinal tract from a single sample. In June 2024, MP Biomedicals, a US-based provider of products, chemicals, and diagnostics, launched immunochromatographic rapid diagnostic kits for gastrointestinal infectious diseases. These kits allow fast and accurate detection of Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. They support rapid, point-of-care qualitative detection, versatile sample use including stool, blood, plasma, serum, water, and food, and are suitable for both clinical and research settings. Using immunochromatographic technology, they support early diagnosis, treatment monitoring, and confirmation of pathogen eradication, offering a combination of speed, precision, and broad pathogen coverage.
In January 2025, Fremman Capital, a UK-based private equity firm focused on healthcare and life sciences investments, acquired a majority stake in DIESSE Diagnostica Senese for an undisclosed sum. Fremman Capital intends to accelerate DIESSE’s international growth and reinforce its position in the specialty in vitro diagnostics market by supporting innovation, expanding the product range for autoimmune and infectious disease diagnostics, and increasing production capacity at DIESSE’s biotech campus, driving long-term sustainable growth. DIESSE Diagnostica Senese is an Italy-based developer of innovative in vitro diagnostics and reagents for autoimmunity, infectious diseases, and hematological testing, serving clinical laboratories worldwide.
Major companies operating in the infectious disease in vitro diagnostics market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare AG, bioMérieux SA, QIAGEN N.V., Becton Dickinson and Company, Hologic Inc., DiaSorin S.p.A., Meridian Bioscience, Quidel Corporation, Revvity Inc., OraSure Technologies Inc., Transasia Bio-Medicals Ltd., Randox Laboratories, Luminex Corporation, Wako Pure Chemical Industries Ltd., Bio-Rad Laboratories Inc., Trivitron Healthcare.
North America was the largest region in the infectious disease in vitro diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the infectious disease in vitro diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the infectious disease IVD market by raising costs for reagents, diagnostic instruments, and laboratory consumables imported from Asia-Pacific and Europe. Molecular diagnostics and reagent segments are most affected, particularly in North America. While tariffs have created pricing challenges for laboratories, they are also driving regional manufacturing investments and strengthening domestic diagnostic supply chains.
The infectious disease in vitro diagnostics market research report is one of a series of new reports that provides infectious disease in vitro diagnostics market statistics, including infectious disease in vitro diagnostics industry global market size, regional shares, competitors with a infectious disease in vitro diagnostics market share, detailed infectious disease in vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease in vitro diagnostics industry. This infectious disease in vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Infectious disease in vitro diagnostics are laboratory tests performed on samples such as blood, urine, or swabs to detect, identify, and monitor infectious pathogens including bacteria, viruses, fungi, and parasites. These diagnostics enable accurate and timely diagnosis, guide treatment decisions, and support disease surveillance and infection control.
The main product types in infectious disease in vitro diagnostics are instruments, reagents, and software and services. Instruments are tools or devices used to measure and monitor environmental conditions including air, water, soil, and noise. They utilize technologies such as molecular diagnostics, immunoassay, microbiology, hematology, urinalysis, and others. Applications include methicillin-resistant Staphylococcus aureus, Clostridium difficile, respiratory viruses, tuberculosis and drug-resistant tuberculosis, gonorrhea, human papillomavirus, human immunodeficiency virus, hepatitis C, hepatitis B, and more. End-users include hospitals, clinics, diagnostic laboratories, academic research institutes, and other organizations.
The infectious disease in vitro diagnostics market consists of revenues earned by entities by providing services such as serology testing, rapid diagnostic testing, disease surveillance and monitoring, sample collection and processing, and consulting and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease in vitro diagnostics market also includes sales of rapid test kits, culture media, controls and calibrators, molecular sequencing kits, flow cytometry reagents, and point-of-care diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Infectious Disease in Vitro Diagnostics Market Characteristics
3. Infectious Disease in Vitro Diagnostics Market Supply Chain Analysis
4. Global Infectious Disease in Vitro Diagnostics Market Trends and Strategies
5. Infectious Disease in Vitro Diagnostics Market Analysis of End Use Industries
7. Global Infectious Disease in Vitro Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Infectious Disease in Vitro Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Infectious Disease in Vitro Diagnostics Market Segmentation
10. Infectious Disease in Vitro Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Infectious Disease in Vitro Diagnostics Market
12. China Infectious Disease in Vitro Diagnostics Market
13. India Infectious Disease in Vitro Diagnostics Market
14. Japan Infectious Disease in Vitro Diagnostics Market
15. Australia Infectious Disease in Vitro Diagnostics Market
16. Indonesia Infectious Disease in Vitro Diagnostics Market
17. South Korea Infectious Disease in Vitro Diagnostics Market
18. Taiwan Infectious Disease in Vitro Diagnostics Market
19. South East Asia Infectious Disease in Vitro Diagnostics Market
20. Western Europe Infectious Disease in Vitro Diagnostics Market
21. UK Infectious Disease in Vitro Diagnostics Market
22. Germany Infectious Disease in Vitro Diagnostics Market
23. France Infectious Disease in Vitro Diagnostics Market
24. Italy Infectious Disease in Vitro Diagnostics Market
25. Spain Infectious Disease in Vitro Diagnostics Market
26. Eastern Europe Infectious Disease in Vitro Diagnostics Market
27. Russia Infectious Disease in Vitro Diagnostics Market
28. North America Infectious Disease in Vitro Diagnostics Market
29. USA Infectious Disease in Vitro Diagnostics Market
30. Canada Infectious Disease in Vitro Diagnostics Market
31. South America Infectious Disease in Vitro Diagnostics Market
32. Brazil Infectious Disease in Vitro Diagnostics Market
33. Middle East Infectious Disease in Vitro Diagnostics Market
34. Africa Infectious Disease in Vitro Diagnostics Market
36. Infectious Disease in Vitro Diagnostics Market Competitive Landscape and Company Profiles
37. Infectious Disease in Vitro Diagnostics Market Other Major and Innovative Companies
40. Infectious Disease in Vitro Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Infectious Disease In Vitro Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses infectious disease in vitro diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for infectious disease in vitro diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The infectious disease in vitro diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Instruments; Reagents; Software And Services2) By Technology: Molecular Diagnostics; Immunoassay; Microbiology
3) By Application: Methicillin-Resistant Staphylococcus Aureus (MRSA); Clostridium Difficile; Respiratory Virus; Tuberculosis (TB) And Drug-Resistant Tuberculosis (TB); Gonorrhea; Human Papillomavirus (HPV); Human Immunodeficiency Virus (HIV); Hepatitis C; Hepatitis B; Other Applications
4) By End-Use: Hospitals And Clinics; Diagnostic Laboratories; Other End-Users
Subsegments:
1) By Instrument: Polymerase Chain Reaction Machines; Immunoassay Analyzers; Microbiology Analyzers; Next Generation Sequencers2) By Reagent: Molecular Reagents; Immunoassay Reagents; Microbiology Reagents; Enzymes And Buffers; Controls And Calibrators
3) By Software And Services: Data Management Software; Laboratory Information Systems; Cloud Based Solutions; Maintenance And Support Services; Consulting And Training Services
Companies Mentioned: F. Hoffmann-La Roche AG; Abbott Laboratories; Danaher Corporation; Thermo Fisher Scientific Inc.; Siemens Healthcare AG; bioMérieux SA; QIAGEN N.V.; Becton Dickinson and Company; Hologic Inc.; DiaSorin S.p.A.; Meridian Bioscience; Quidel Corporation; Revvity Inc.; OraSure Technologies Inc.; Transasia Bio-Medicals Ltd.; Randox Laboratories; Luminex Corporation; Wako Pure Chemical Industries Ltd.; Bio-Rad Laboratories Inc.; Trivitron Healthcare
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Infectious Disease in Vitro Diagnostics market report include:- F. Hoffmann-La Roche AG
- Abbott Laboratories
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Siemens Healthcare AG
- bioMérieux SA
- QIAGEN N.V.
- Becton Dickinson and Company
- Hologic Inc.
- DiaSorin S.p.A.
- Meridian Bioscience
- Quidel Corporation
- Revvity Inc.
- OraSure Technologies Inc.
- Transasia Bio-Medicals Ltd.
- Randox Laboratories
- Luminex Corporation
- Wako Pure Chemical Industries Ltd.
- Bio-Rad Laboratories Inc.
- Trivitron Healthcare
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 16.13 Billion |
| Forecasted Market Value ( USD | $ 21.25 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
